AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01190930
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01190930
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01190930
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01190930
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, PO, or IV
Trial: NCT03749018
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03749018
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00766142
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00766142
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00482898
Drug: MK0359
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01845649
Drug: WC3011 Estradiol Vaginal Cream
RxNorm normalized name: Estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily for 14 days followed by 3 times per week for 10 weeks
Trial: NCT01845649
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily for 14 days followed by 3 times per week for 10 weeks
Trial: NCT03884062
Drug: DAAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lab, U/S, Fibroscan \& CT if needed
Trial: NCT03511378
Drug: Neulasta®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Neulasta®
Trial: NCT02041221
Drug: SPARC1316 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive SPARC1316.
Trial: NCT02041221
Drug: SPARC1316 Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02041221
Drug: SPARC1316 Dose 4
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02041221
Drug: SPARC1316 Dose 5
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04571697
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: No intervention or treatment will be administered as part of this study. Data of participants with first claim for a methotrexate in the patient's history are included.
Trial: NCT04571697
Drug: Anti-TNF
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention or treatment will be administered as part of this study. Data of participants with first claim for an anti-TNF in the patient's history are included. Anti-TNF includes infliximab, golimumab, etanercept, certolizumab, and adalimumab.
Trial: NCT00632931
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1).
Trial: NCT05082662
Drug: Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One Diclofenac tablet was administered orally.
Trial: NCT05082662
Drug: Cataflam® 50 coated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Diclofenac tablet was administered orally.
Trial: NCT02176382
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: zoledronic acid infusion
Trial: NCT03220776
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 day trial of matched placebo
Trial: NCT01780545
Drug: OGX-427
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.~Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity.
Trial: NCT02814097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of placebo administered once daily for 28 consecutive days
Trial: NCT03146325
Drug: BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE
RxNorm normalized name: bismuth biskalcitrate / metronidazole / tetracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 14-day quadruple Hp eradication therapy consisting of: omeprazole (20 mg twice daily) plus 3 capsules q.i.d., each containing 420 mg of bismuth subcitrate potassium, 375 mg of metronidazole and 375 mg of tetracycline hydrochloride, for 14 days
Trial: NCT03146325
Drug: MATCHING PLACEBO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TO BE PREPARED BY LICENSED COMPOUNDING PHARMACY
Trial: NCT04672499
Drug: Placebo 150 mg tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match miricorilant 150 mg tablets for oral administration
Trial: NCT02166047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match vesatolimod tablet administered orally
Trial: NCT01639014
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules
Trial: NCT03193216
Drug: Alginates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid Alginate therapy will be added to twice daily PPI regimen. Patients will be asked to take the alginate solution four times daily (following meals and at bedtime) at 10ml/dose.
Trial: NCT01165502
Drug: CM3.1-AC100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAD study with repeated subcutaneous (sc) doses
Trial: NCT01165502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for compound CM3.1-AC100 s.c.
Trial: NCT03402321
Drug: Alvogyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paste form with analgesic action to protect the palatal donor site and help to relief pain
Trial: NCT02223871
Drug: Artemether 20 mg and lumefantrine 120mg combination tablet:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue treatment to ensure clearance of Plasmodium falciparum comprising six doses of four tablets (total course of 24 tablets) given over a period of 60 hours. Each dose of tablets administered orally was immediately followed by food or drinks rich in fat (e.g., milk).
Trial: NCT01006265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered orally once daily
Trial: NCT02538718
Drug: YTP(Ritodrine)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01176435
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solution taken orally three times a day.
Trial: NCT01176435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution taken orally three times a day.
Trial: NCT03825016
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Diclofenac Sodium
Trial: NCT00026013
Drug: hypericum perforatum
RxNorm normalized name: Hypericum perforatum
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03650361
Drug: Differin 0.3% Topical Gel
RxNorm normalized name: Differin 0.3% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
Trial: NCT03116672
Drug: one dose ketorolac 10 mg
RxNorm normalized name: ketorolac Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of ketorolac 10mg, (Dolac) 15 minutes before the clinical procedure.
Trial: NCT03116672
Drug: One dose Diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of diclofenac, (Diclofenaco) 15 minutes before the clinical procedure.
Trial: NCT03116672
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Placebo, 15 minutes before the clinical procedure.
Trial: NCT04059172
Drug: Ibuprofen 200 mg and acetaminphen 650 mg
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively.
Trial: NCT04059172
Drug: Ibuprofen 200 mg
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively.
Trial: NCT04059172
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively.
Trial: NCT02354014
Drug: Background Regimen (BR)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) medications will be dosed according to World Health Organization (WHO) guidelines, National Tuberculosis Program (NTP) guidelines and current standard of care at the site.
Trial: NCT02554903
Drug: Placebo sugar pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
Trial: NCT01885936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
Trial: NCT01470664
Drug: FST-100 Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FST-100 Vehicle
Trial: NCT03500263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02223013
Drug: BIBV 308 SE solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02223013
Drug: BIBV 308 SE capsule S
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03703349
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Magnesium
Trial: NCT01208090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
Trial: NCT03807700
Drug: Experimental Denture Adhesive
RxNorm normalized name: ALCOHOL,DENATURED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
Trial: NCT02554552
Drug: YY1201 2ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YY1201 2ml
Trial: NCT02554552
Drug: Placebo 2ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phosphate buffered saline 2ml
Trial: NCT03899155
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT04595565
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/m² day 1-14 q21 day cycle for eight cycles
Trial: NCT03899155
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT03899155
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT04323332
Drug: Traditional Chinese Medicine Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.
Trial: NCT00439647
Drug: Zoledronic acid 5 mg iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronic acid 5 mg iv given once a year.
Trial: NCT00439647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous (i.v.) once a year
Trial: NCT01011127
Drug: pravastatin, rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02579967
Drug: Myeloablative Conditioning-Closed with amendment L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentostatin 4 mg/m2/day IV on days -13 and -9, low-dose cyclophosphamide orally daily on days -13 through -6; busulfan IV, pharmokinetically dosed, on days -5, -4, -3, and -2. (Closed with amendment L)
Trial: NCT03642626
Drug: Cyclophosphamide 500 mg/m2; 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine
Trial: NCT03642626
Drug: Cyclophosphamide 500 mg/m2; 3 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine
Trial: NCT03642626
Drug: Cyclophosphamide 250 mg/m2; 3 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine
Trial: NCT03642626
Drug: Abecma, Intravenous Suspension
RxNorm normalized name: Abecma, intravenous suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.
Trial: NCT02513979
Drug: Angiotensin type II receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin type II receptor antagonists given to hypertensive patients treated with high blood pressure
Trial: NCT03403556
Drug: Rosuvamibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10mg/Ezetimibe10mg qd for 24 weeks
Trial: NCT03403556
Drug: Monorova
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20mg qd for 24 weeks
Trial: NCT03175835
Drug: Rosuvastatin 20 mg
RxNorm normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1\~Day5
Trial: NCT03175835
Drug: Rosuvastatin 20 mg & CKD-519 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22\~Day26
Trial: NCT03305471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching stock solution in bottle
Trial: NCT03229096
Drug: Apatinib plus XELOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle.~Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week).~Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks.
Trial: NCT02846532
Drug: Acetylsalicylic Acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.
Trial: NCT00095017
Drug: MK0663, etoricoxib / Duration of Treatment: 4 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00212797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04072575
Drug: PP6M injection Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.
Trial: NCT00120822
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00245440
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg tablets; 2 tablets once daily (500 mg) for 3 days
Trial: NCT00245440
Drug: Telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg tablets; 2 tablets once daily (800 mg) for 5 days
Trial: NCT02473289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo on Day 1, 28 and 56.
Trial: NCT00544115
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00544115
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04723732
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% solution of sodium chloride, containing 9 g/L Sodium Chloride (154 mEq/L sodium and 154 mEq/L chloride)
Trial: NCT03466411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as IV infusion.
Trial: NCT02831998
Drug: ZuraPrep
RxNorm normalized name: DuraPrep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically.
Trial: NCT03638258
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied once daily for 12 weeks
Trial: NCT00359385
Drug: Alendronate 70mg weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70mg weekly
Trial: NCT03489837
Drug: Levotuss
RxNorm normalized name: levothyroxine sodium Oral Tablet [Levotabs]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral taken
Trial: NCT03150693
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV, PO
Trial: NCT03150693
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03150693
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03150693
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV